On March 19, 2024, the Connecticut Appellate Court upheld an employer's right to discharge an employee for being impaired on the job from medical marijuana under a state law.
The Second Circuit U.S. Court of Appeals has reinstated an antitrust complaint brought by pharma firm, Regeneron Pharmaceuticals, Inc., against the Swiss pharmaceutical.
On March 12, the U.S. Court of Appeals for the Second Circuit issued an important decision that sheds light on the test for determining scienter under the federal Anti-Kickback Statute (AKS).
The US Food and Drug Administration (FDA) published a Final Rule on March 22, 2024, amending its regulation at 21 C.F.R. § 170.105 to provide additional bases upon which the agency may determine that a Food Contact Notification (FCN) is no longer effective.
Amending prior requirements, medical device manufacturers and importers have two years to comply with FDA's Quality Management System Regulation final rule, a similar approach to prior good manufacturing practices but with several notable changes.